Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: clinical report

CADTH
Record ID 32018002218
English
Original Title: Tisagenlecleucel (Kymriah) for pediatric acute lymphoblastic leukemia and diffuse large b-cell lymphoma
Authors' objectives: The objectives of this clinical review were to systematically evaluate the benefits and harms of tisagenlecleucel in: (1) children and young adults with r/r B-cell ALL; and (2) adults with r/r DLBCL. This project is a component of a larger CADTH Health Technology Assessment (HTA) to assess clinical effectiveness, cost-effectiveness, patient and caregiver perspectives and experiences, ethical issues, and implementation.
Details
Project Status: Completed
URL for project: https://cadth.ca/tisagenlecleucel-kymriah-pediatric-acute-lymphoblastic-leukemia-and-diffuse-large-b-cell-lymphoma
URL for protocol: https://cadth.ca/sites/default/files/pdf/OP0538_tisagenlecleucel_clinical_review_protocol.pdf
Year Published: 2019
URL for published report: https://cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-clinical-report_jan2019.pdf
URL for additional information: https://cadth.ca/tisagenlecleucel-kymriah-pediatric-acute-lymphoblastic-leukemia-and-diffuse-large-b-cell-lymphoma
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Child
  • Adolescent
  • Lymphoma, Large B-Cell, Diffuse
  • Immunotherapy, Adoptive
  • Young Adult
  • Antineoplastic Agents, Immunological
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
Keywords
  • Acute lymphoblastic leukemia
  • Pediatric
  • Child
  • CAR T-cell therapy
  • Tisagenlecleucel
  • Kymriah
  • Lymphoma
  • Adult
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.